This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
AngioDynamics (ANGO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AngioDynamics (ANGO) closed the most recent trading day at $5.50, moving +0.18% from the previous trading session.
Here's Why AngioDynamics (ANGO) Gained But Lagged the Market Today
by Zacks Equity Research
In the most recent trading session, AngioDynamics (ANGO) closed at $5.99, indicating a +1.7% shift from the previous trading day.
AngioDynamics (ANGO) Divests Its PICC & Midline Businesses
by Zacks Equity Research
AngioDynamics (ANGO) finalizes its PICC and Midline businesses divestment to Spectrum Vascular to optimize its product portfolio and to focus on strengthening its med tech segment.
Why AngioDynamics (ANGO) Outpaced the Stock Market Today
by Zacks Equity Research
AngioDynamics (ANGO) closed at $6.17 in the latest trading session, marking a +1.31% move from the prior day.
AngioDynamics (ANGO) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
The latest trading day saw AngioDynamics (ANGO) settling at $6.09, representing a -0.98% change from its previous close.
AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment
by Zacks Equity Research
AngioDymics' (ANGO) new FDA-approved Auryon XL Catheter is likely to boost PAD treatment by eliminating access site complications in Atherectomy procedures.
AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in second-quarter fiscal 2024.
AngioDynamics (ANGO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 44.44% and 3.15%, respectively, for the quarter ended November 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why AngioDynamics (ANGO) Outpaced the Stock Market Today
by Zacks Equity Research
The latest trading day saw AngioDynamics (ANGO) settling at $7.63, representing a +1.87% change from its previous close.
AngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
AngioDynamics (ANGO) closed at $6.91 in the latest trading session, marking a -0.72% move from the prior day.
AngioDynamics (ANGO) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
AngioDynamics (ANGO) closed the most recent trading day at $6.77, moving -1.31% from the previous trading session.
CVRx (CVRX) Moves 7.1% Higher: Will This Strength Last?
by Zacks Equity Research
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AngioDynamics (ANGO) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the most recent trading session, AngioDynamics (ANGO) closed at $6.74, indicating a -0.15% shift from the previous trading day.
AngioDynamics (ANGO) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
AngioDynamics (ANGO) closed the most recent trading day at $6.85, moving +1.33% from the previous trading session.
AngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the latest trading session, AngioDynamics (ANGO) closed at $6.86, marking a -1.15% move from the previous day.
AngioDynamics (ANGO) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, AngioDynamics (ANGO) stood at $6.21, denoting a +0.65% change from the preceding trading day.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2024.
AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 14.29% and 1.32%, respectively, for the quarter ended August 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics (ANGO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AngioDynamics (ANGO) closed at $7.02 in the latest trading session, marking a -0.71% move from the prior day.
Avid Bioservices (CDMO) Reports Break-Even Earnings for Q1
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 100% and 10.96%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AngioDynamics (ANGO) closed at $8.15, marking a +1.88% move from the previous day.
AngioDynamics (ANGO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AngioDynamics (ANGO) closed the most recent trading day at $8.76, moving -1.35% from the previous trading session.